Literature DB >> 24816460

Synthetic mRNAs for manipulating cellular phenotypes: an overview.

Elgar Susanne Quabius1, Guido Krupp2.   

Abstract

Availability of high quality synthetic mRNAs (syn-mRNAs) has enabled progress in their applications. Important structural features and quality requirements are discussed. Developments in the application of mRNA-mediated manipulation of cells are presented (i) mRNA-directed expression of antigens in dendritic cells for vaccination projects in oncogenesis, infectious disease and allergy prevention; (ii) reprogramming of human fibroblasts to induced pluripotent stem cells with their subsequent differentiation to the desired cell type; (iii) applications in gene therapy.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24816460     DOI： 10.1016/j.nbt.2014.04.008

Source DB:  PubMed          Journal:  N Biotechnol        ISSN： 1871-6784            Impact factor:   5.079


  21 in total

1.  V-Maf Musculoaponeurotic Fibrosarcoma Oncogene Homolog A Synthetic Modified mRNA Drives Reprogramming of Human Pancreatic Duct-Derived Cells Into Insulin-Secreting Cells.

Authors:  Elisa Corritore; Yong-Syu Lee; Valentina Pasquale; Daniela Liberati; Mei-Ju Hsu; Catherine Anne Lombard; Patrick Van Der Smissen; Amedeo Vetere; Susan Bonner-Weir; Lorenzo Piemonti; Etienne Sokal; Philippe A Lysy
Journal:  Stem Cells Transl Med       Date:  2016-07-12       Impact factor: 6.940

Review 2.  Recent Developments in mRNA-Based Protein Supplementation Therapy to Target Lung Diseases.

Authors:  Itishri Sahu; A K M Ashiqul Haque; Brian Weidensee; Petra Weinmann; Michael S D Kormann
Journal:  Mol Ther       Date:  2019-03-06       Impact factor: 11.454

3.  Biomaterials for mRNA delivery.

Authors:  Mohammad Ariful Islam; Emma K G Reesor; Yingjie Xu; Harshal R Zope; Bruce R Zetter; Jinjun Shi
Journal:  Biomater Sci       Date:  2015-08-17       Impact factor: 6.843

Review 4.  Viral and Synthetic RNA Vector Technologies and Applications.

Authors:  Juliane W Schott; Michael Morgan; Melanie Galla; Axel Schambach
Journal:  Mol Ther       Date:  2016-07-05       Impact factor: 11.454

Review 5.  RNA therapeutics for cardiovascular disease.

Authors:  Christian Boada; Roman Sukhovershin; Roderic Pettigrew; John P Cooke
Journal:  Curr Opin Cardiol       Date:  2021-05-01       Impact factor: 2.161

Review 6.  Modified mRNA-Based Vaccines Against Coronavirus Disease 2019.

Authors:  Aline Yen Ling Wang
Journal:  Cell Transplant       Date:  2022 Jan-Dec       Impact factor: 4.139

7.  Cap analogs modified with 1,2-dithiodiphosphate moiety protect mRNA from decapping and enhance its translational potential.

Authors:  Malwina Strenkowska; Renata Grzela; Maciej Majewski; Katarzyna Wnek; Joanna Kowalska; Maciej Lukaszewicz; Joanna Zuberek; Edward Darzynkiewicz; Andreas N Kuhn; Ugur Sahin; Jacek Jemielity
Journal:  Nucleic Acids Res       Date:  2016-10-07       Impact factor: 16.971

Review 8.  mRNA capping: biological functions and applications.

Authors:  Anand Ramanathan; G Brett Robb; Siu-Hong Chan
Journal:  Nucleic Acids Res       Date:  2016-06-17       Impact factor: 16.971

9.  Recombinant Vaccinia virus-coded interferon inhibitor B18R: Expression, refolding and a use in a mammalian expression system with a RNA-vector.

Authors:  Yuriy G Kim; Aliya Zh Baltabekova; Erzhan E Zhiyenbay; Altynai S Aksambayeva; Zhadyra S Shagyrova; Rinat Khannanov; Erlan M Ramanculov; Alexandr V Shustov
Journal:  PLoS One       Date:  2017-12-07       Impact factor: 3.240

10.  Hit-and-run programming of therapeutic cytoreagents using mRNA nanocarriers.

Authors:  H F Moffett; M E Coon; S Radtke; S B Stephan; L McKnight; A Lambert; B L Stoddard; H P Kiem; M T Stephan
Journal:  Nat Commun       Date:  2017-08-30       Impact factor: 14.919
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.